A new cheek swab, known as AlphaID (Grifols), has been made available for physicians to screen patients with chronic obstructive pulmonary disease (COPD) for alpha-1 antitrypsin deficiency (Alpha-1).
Among patients with severe asthma, benralizumab treatment improved nasal symptoms, which worsen with increasing baseline blood eosinophil count.
In a real-world setting, mepolizumab therapy significantly reduced the rate of asthma exacerbations and their related costs.
Children with a family history of cancer may be more likely to develop childhood asthma.
Fractional exhaled nitric oxide values may help in the identification of cough variant asthma in patients with chronic cough.
Mepolizumab was associated with reductions in eosinophil levels and asthma exacerbations,
as well as improvements in quality of life in uncontrolled severe eosinophilic asthma.
Asthma plus atopic dermatitis may lead to poorer sleep-specific outcomes in pediatric patients.
Mepolizumab reduced the number of exacerbations in patients with severe asthma, but exacerbations per month remained relatively stable throughout the year without a clear seasonal influence.
Dupilumab has demonstrated consistency in effective asthma control across baseline levels of immunoglobulin E among individuals with uncontrolled, moderate to severe asthma with high baseline eosinophils.
Overall, there was a decrease in asthma exacerbations, improvement in ACT scores, and improvement in FEV1%-predicted.
